NDA Submitted for Niraparib Plus Abiraterone Acetate + Prednisone for Prostate Cancer
The NDA for niraparib plus abiraterone acetate and prednisone has been submitted to the FDA for patients with BRCA-positive mCRPC.
Source: empr.com
Page 6 - Peter Lebowitz News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Peter Lebowitz. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Peter Lebowitz Today - Breaking & Trending Today
Janssen submits marketing application for talquetamab
European Medicines Agency will consider therapy for the treatment of patients with multiple myeloma - News - PharmaTimes
Source: pharmatimes.com
Janssen submits MAA to European Medicines Agency for talquetamab
The Janssen Pharmaceutical Companies of Johnson & Johnson has submitted a marketing authorisation application (MAA) to the European Medicines Agency (EMA) for talquetamab to treat patients suffering with relapsed or refractory multiple myeloma (RRMM).
Janssen Submits Marketing Authorisation Application to the European Medicines Agency Seeking Approval of Talquetamab for the Treatment of Patients wi
Janssen Submits Marketing Authorisation Application to the European Medicines Agency Seeking Approval of Talquetamab for the Treatment of Patients with Relapsed or Refractory Multiple MyelomaBEERSE, BELGIUM, 3 January 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the subm...
Source: pharmiweb.com
Janssen submits MAA for bispecific t-cell engager antibody
Approval for Janssen’s talquetamab to treat relapsed/refractory multiple myeloma has been submitted to the European Medicines Agency.
Source: europeanpharmaceuticalreview.com